Cyclooxygenases: down-regulation and the influence on the gene expression
Public support
Provider
Ministry of Health
Programme
Branch programm of research of the Ministry of Health
Call for proposals
VaV pro Ministerstvo zdravotnictví 3 (SMZ02006NR)
Main participants
—
Contest type
VS - Public tender
Contract ID
NR8760-4/2006
Alternative language
Project name in Czech
Cyklooxygenázy: down-regulace a ovlivnění genové exprese
Annotation in Czech
Úkolem této studie je porozumění změn v genové expresi na buněčné úrovni v souvislosti se zablokováním exprese COX1 resp. COX2 pomocí RNA interference (RNAi). Pomocí RNAi, syntetických siRNA nebo shRNA exprimujících plasmidů či retrovirů, budou vytvořenybuněčné linie se zablokovanou expresí COX1 resp. COX2. Profil genové exprese bude určen pomocí DNA mikročipů srovnáním s mateřskou linií a ověřením pomocí real-time PCR. Na základě prvních výsledků bude sestaven experimentální jednoúčelový DNA mikročipobsahující vybrané geny. Na základě výsledků bude posouzena fyziologická funkce COX1 a COX2 v souvislosti s absencí jedné z izoforem.
Scientific branches
R&D category
NV - Nonindustrial research (Applied research excluded Industrial research)
CEP classification - main branch
EB - Genetics and molecular biology
CEP - secondary branch
EI - Biotechnology and bionics
CEP - another secondary branch
FR - Pharmacology and apothecary chemistry
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
10603 - Genetics and heredity (medical genetics to be 3)<br>10604 - Reproductive biology (medical aspects to be 3)<br>10605 - Developmental biology<br>10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods<br>20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30101 - Human genetics<br>30104 - Pharmacology and pharmacy<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
In the project the cell line with the inhibition of COX1 was prepared. The relationship between COX1 and genes related to metabolism of AA was studied by RT PCR and DNA microarrays. The relation to PGES1 and ABCC4 was found.
Solution timeline
Realization period - beginning
Jan 1, 2006
Realization period - end
Dec 31, 2009
Project status
U - Finished project
Latest support payment
Dec 18, 2009
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP10-MZ0-NR-U/03:3
Data delivery date
Apr 27, 2011
Finance
Total approved costs
6,423 thou. CZK
Public financial support
6,370 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
53 thou. CZK